Safety and early curative efficacy of lipocyte bioactive secretion in preventing white matter injury of premature infants
10.3760/cma.j.issn.2095-428X.2018.19.013
- VernacularTitle:脂肪干细胞生物活性分泌物防治早产儿脑白质损伤的安全性及早期疗效
- Author:
Yichong CAO
1
;
Weipeng LIU
;
Feng WANG
;
Qian WANG
;
Zhaoyan WANG
;
Yinxiang YANG
;
Qiaozhi YANG
;
Qian ZHANG
;
Fang LIU
;
Lijun LIU
;
Hongyan LYU
;
Shifang TANG
;
Jiajie ZHANG
;
Zhijie WEN
;
Zuo LUAN
Author Information
1. 中国人民解放军医学院
- Keywords:
Stem cells;
Infant;
premature;
White matter injury;
Lipid stem cells bioactive secretion
- From:
Chinese Journal of Applied Clinical Pediatrics
2018;33(19):1503-1507
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the safety and efficacy of intrathecal administration of adipose stem cells de-rived from bioactive secretome (ASCBS)in treatment of whiter matter injury (WMI)in the preterm infants. Methods Sixty - three cases of WMI were recruited according to the uniform standards from multiple medical centers and they were divided into 3 gestational age (GA)subgroups,which were 21 cases in group A (GA 24 - 28 + 6 ),20 cases in group B (GA 29 - 32 + 6 ),and 22 cases in group C (GA 33 - 36 + 6 ). The patients were randomly divided into treatment groups and control groups by tossing coins. The treatment groups received lumbar puncture followed with ASCBS intra-thecal injection once daily for 3 consecutive days. Follow - up study included Neonatal Behavioral Neurological Assess-ment (NBNA)at term - equivalent age and neurodevelopment at corrected age of 6 - month. Neurodevelopment was assessed by using the Bayley Scales of Infant Development and Peabody Developmental Motor Scale. The survival rates, NBNA scores,mental development index (MDI),psychomotor develop index (PDI),total motor development quotient, gross motor development quotient and fine motor development among each subgroup were compared. Results Sixty -three cases were recruited,including 31 in the treatment group and 32 in the control group. Only 1 case in the treatment groups lost in the follow - up. No clinical side effects were found in the treatment groups. There was no significant diffe-rence in the survival rate and complication in the preterms in all subgroups of the treatment group and control group (all P > 0. 05). The gross and total motor development quotient in the treatment group A was higher than that in the control group A(gross motor development quotient:98. 330 ± 6. 282 in treatment group A,90. 330 ± 3. 777 in control group A, P = 0. 040;total motor development quotient:97. 330 ± 4. 803 in treatment group A,91. 000 ± 4. 472 in control group A,P = 0. 023). The rest findings showed no significant difference between groups. Conclusion The treatment of WMI in preterm infants with ASCBS is safe and can promote the motor development of preterm infants with GA in 24 - 28 weeks.
